164 related articles for article (PubMed ID: 9743368)
1. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
2. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of Th1 and Th2 L-selectin--CD4+ tumor-reactive T cells.
To WC; Seeley BM; Barthel SW; Shu S
Laryngoscope; 2000 Oct; 110(10 Pt 1):1648-54. PubMed ID: 11037819
[TBL] [Abstract][Full Text] [Related]
4. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
5. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
6. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
Meijer SL; Dols A; Hu HM; Chu Y; Romero P; Urba WJ; Fox BA
Cell Immunol; 2004 Feb; 227(2):93-102. PubMed ID: 15135291
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
9. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
Kagamu H; Shu S
J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
11. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
Winter H; Hu HM; Poehlein CH; Huntzicker E; Osterholzer JJ; Bashy J; Lashley D; Lowe B; Yamada J; Alvord G; Urba WJ; Fox BA
Immunology; 2003 Mar; 108(3):409-19. PubMed ID: 12603608
[TBL] [Abstract][Full Text] [Related]
12. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
13. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines.
Schweighoffer T; Schmidt W; Buschle M; Birnstiel ML
Gene Ther; 1996 Sep; 3(9):819-24. PubMed ID: 8875231
[TBL] [Abstract][Full Text] [Related]
14. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
16. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
Aruga A; Aruga E; Chang AE
Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
[TBL] [Abstract][Full Text] [Related]
17. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
20. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
Kircheis R; Küpcü Z; Wallner G; Wagner E
Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
